Abstract: A document processing system comprising an image capture subsystem for capturing selected image metrics and at least one image rendition from a plurality of documents and for determining if at least one of the selected image metrics for any of the at least one image rendition does not successfully compare against preselected image quality metric threshold values. An image quality flag is generated for any of the at least one image rendition if it does not successfully compare, and a record entry for each imaged document having at least one flagged image rendition is created in an image quality flag file. An image index file for individually accessing the image renditions is modified to include a reference to the corresponding image quality flag file record entry The document processing system may optionally compare selected document metrics against preselected document metrics in a similar manner.

Abstract: An image quality assurance method for identifying image defects in a plurality of previously-imaged documents, where each previously-imaged document includes at least one image rendition stored in at least one image rendition file according to type of image rendition. The image renditions are analyzed to provide selected image metrics, the latter of which are compared against preselected image quality metric threshold values. An image quality flag is generated for any image rendition if at least one of the selected image metrics for that image rendition does not successfully compare against the preselected image quality metric threshold values. A record entry is created in an image quality flag file for those documents having at least one flagged image rendition, the record entry including information about the selected image metrics of the at least one flagged image rendition for that imaged document.

Abstract: A modular electronics enclosure for one or more circuit card assembly includes top and bottom lids formed substantially the same with at least one intermediate circuit card support member disposed therebetween. At least one spring clip clamps the top and bottom lids together around the intermediate support member.

Abstract: An image quality assurance method for identifying image defects in a plurality of imaged documents, where each imaged document includes at least one image rendition. The image renditions are analyzed to provide selected image metrics, the latter of which are compared against preselected image quality metric threshold values. An image quality flag is generated for any image rendition if at least one of the selected image metrics for that image rendition does not successfully compare against the preselected image quality metric threshold values. A record entry is created in an image quality flag file for those documents having at least one flagged image rendition, the record entry including information about the selected image metrics of the at least one flagged image rendition for that imaged document. Image defects in a plurality of imaged documents can be identified by examining the record entries in the image quality flag file.

Abstract: GDNFR?, GDNFR? extracellular domain (ECD), GDNFR? variants, chimeric GDNFR? (e.g., GDNFR? immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR?-ligands, for example GDNF, by providing GDNFR? to the cell. Also provided are methods for using GDNFR?, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.

Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.

Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.

Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.

Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.

Abstract: GDNFR&agr;, GDNFR&agr; extracellular domain (ECD), GDNFR&agr; variants, chimeric GDNFR&agr; (e.g., GDNFR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR&agr;-ligands, for example GDNF, by providing GDNFR&agr; to the cell. Also provided are methods for using GDNFR&agr;, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

Abstract: GDNFR&agr;, GDNFR&agr; extracellular domain (ECD), GDNFR&agr; variants, chimeric GDNFRae (e.g., GDNFR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR&agr;-ligands, for example GDNF, by providing GDNFR&agr; to the cell. Also provided are methods for using GDNFR&agr;, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.

Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.

Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.

Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN. by providing NTNR&agr; to the cell.

Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.

Abstract: The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds.

Abstract: NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR.alpha.-ligands, for example NTN, by providing NTNR.alpha. to the cell.

Abstract: A rate-of-flow control valve assembly actuable as a function of velocity of fluid in a conduit includes a sensing plate projecting into the conduit, substantially perpendicular to a direction of flow in the conduit and a sleeve valve located downstream of the sensing plate. The sleeve valve includes a substantially cylindrical, flexible rubber sleeve surrounded by a control chamber, and an outer rigid sleeve, the flexible sleeve adapted to vary the flow rate of the fluid through the sleeve valve. Also included is a spool valve controller operatively connected to the sensing plate and in communication with the control chamber in the sleeve valve, the spool valve operable to control the flow of fluid into and out of the control chamber as a function of movement of the sensing plate in the conduit.